Phase 1 study: Tetrahydrouridine-Decitabine, DNA methyltransferase and cytidine deaminase inhibitor combo.

This Phase 1 trial from EpiDestiny, Inc. evaluates weekly oral administrations of tetrahydrouridine followed by decitabine over 24 weeks in patients with relapsed or refractory myelodysplastic syndromes. The study focuses on safety, toxicity, and potential clinical benefit, with clinic visits every 4 weeks in the Bronx.